Urogen Pharma Stock Analysis

UroGen Stock Analysis Notes

About 87.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 239.57. UroGen Pharma recorded a loss per share of 2.96. The entity had not issued any dividends in recent years. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Urogen Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 201 people. For more information please call Elizabeth Barrett at 646 768 9780 or visit https://www.urogen.com.

UroGen Pharma Investment Alerts

UroGen Pharma Upcoming and Recent Events

UroGen Largest EPS Surprises

View All Earnings Estimates

UroGen Pharma Environmental, Social, and Governance (ESG) Scores

UroGen Stock Institutional Investors

Note, although UroGen Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

UroGen Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 554.05 M.

UroGen Profitablity

The company has Profit Margin (PM) of (1.4) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.08) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.08.

Management Efficiency

UroGen Pharma has return on total asset (ROA) of (0.2578) % which means that it has lost $0.2578 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.8126) %, meaning that it created substantial loss on money invested by shareholders. UroGen Pharma's management efficiency ratios could be used to measure how well UroGen Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Equity is likely to grow to 15.13, while Return On Tangible Assets are likely to drop (0.47). At this time, UroGen Pharma's Total Assets are very stable compared to the past year. As of the 22nd of March 2025, Other Current Assets is likely to grow to about 10.4 M, though Net Tangible Assets are likely to grow to (97.6 M).

Technical Drivers

As of the 22nd of March, UroGen Pharma has the Risk Adjusted Performance of 0.0282, coefficient of variation of 4148.1, and Semi Deviation of 2.94. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of UroGen Pharma, as well as the relationship between them.

UroGen Pharma Price Movement Analysis

UroGen Pharma Insider Trading Activities

UroGen Pharma Outstanding Bonds

UroGen Pharma Predictive Daily Indicators

UroGen Pharma Corporate Filings

UroGen Pharma Forecast Models

UroGen Pharma's time-series forecasting models are one of many UroGen Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary UroGen Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how UroGen Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling UroGen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as UroGen Pharma. By using and applying UroGen Stock analysis, traders can create a robust methodology for identifying UroGen entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. UroGen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. UroGen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

UroGen Pharma stock analysis indicators help investors evaluate how UroGen Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading UroGen Pharma shares will generate the highest return on investment. By understating and applying UroGen Pharma stock analysis, traders can identify UroGen Pharma position entry and exit signals to maximize returns.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.